One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
Article Sep 21, 2016
A large biomarker-genome-wide association study (GWAS) has shown that genetic variation affects blood biomarkers in patients with chronic obstructive lung disease (COPD). Genome-wide genotyping and blood measurements of 88 biomarkers in two NIH-supported clinical cohorts of smokers (1,340 subjects) identified more than 300 novel DNA variants that influence measurement of blood protein levels. Over 30 research institutes from across the US were involved in the study led by University of North Carolina at Chapel Hill, North Carolina, and National Jewish Health, Colorado.
Precision medicine aims to improve patient healthcare by providing individualised treatment choices based on a person’s genetics, environment and lifestyle. For complex diseases such as chronic obstructive lung disease(COPD), this approach will require extensive use of biomarkers and an in-depth understanding of how genetic, epigenetic, and environmental variations contribute to phenotypic diversity and disease progression. Genome-wide association studies linking disease phenotypes to single nucleotide polymorphism (SNP) markers have successfully identified genes and pathways involved in complex disease phenotypes; this study provides concrete links between SNPs and known COPD blood protein biomarkers. The meta-analysis from the cohorts of current and former smokers with and without COPD (SPIROMICS and COPDGene) demonstrate the power of a study which uses a large number of subjects and includes validation cohorts.
Data from selected biomarker blood proteins measurements, genotyping and four clinical COPD phenotypes (airflow obstruction, emphysema, exacerbation history and chronic bronchitis) were combined and statistically analysed to identify pQTLs with a significant relationship to the established clinical phenotypes. The team went on to demonstrate that including SNP data with blood biomarker levels can improve the ability of predictive models to reflect the variation and relationship between biomarker and disease features within COPD, taking us one step closer to precision methods for detecting and treating COPD and complex chronic diseases in general.
The reproducibility crisis is holding back science. London-based Labstep, a start-up out of Oxford University, think that their tool can help make science more open and reproducible. That claim has now been given some concrete evidence with the announcement that the research contingent of the MRC Unit The Gambia at LSHTM will be trialling Labstep across their Banjul-based facility.READ MORE
Researchers have identified a mechanism by which brain-derived neurotrophic factor (BDNF) can suppress GABAergic transmission in hippocampus. In this article, Dr. Rajamani Selvam explains how he and his team achieved these results, and their potential impact on the treatment of neurological disease.READ MORE
High-throughput single-cell analysis has been regularly acclaimed as a transformative technology for sequencing and a huge step towards the goal of personalized medicine. Will Tapestri, a sequencing platform developed by Mission Bio, be the game-changer in DNA analysis we have been waiting for?READ MORE